Leon F. Stankowski, Charles River Laboratories - Qepler Summits And Conferences

Leon F. Stankowski

Senior Scientific Director, Genetic and In Vitro Toxicology
Charles River Laboratories
Chicago, USA
Charles River provides products and services to help expedite the discovery, early-stage development and safe manufacture of novel drugs and therapeutics.

Leon F. Stankowski, Jr., PhD, is currently Senior Scientific Director for Genetic and In Vitro Toxicology at Charles River Laboratories in Skokie, IL.

He obtained BS degrees in premedicine and biophysics from The Pennsylvania State University, and received his PhD in biomedical sciences (genetics) from the University of Tennessee – Oak Ridge Graduate School of Biomedical Science.

Leon has previously worked at multiple other contract research organizations, and also spent three years managing the genetic toxicology group at Johnson & Johnson PRD.

Leon has authored or coauthored dozens of peer-reviewed and invited papers/presentations, and over 100 posters/talks. He served/serves on numerous industrial and regulatory workgroups including ASTM, ILSI-HESI GTTC, IWGT and US EPA, and was/is a member of most of the expert workgroups that revised and/or drafted OECD genotoxicity test guidelines.

Leon has been a member of the Genetic Toxicology Association (GTA) and the Environmental Mutagenesis and Genomics Society for more years than he cares to admit.

He has been an editorial board member for Environmental and Molecular Mutagenesis, and a reviewer for that and multiple other journals.

In GTA, he has served as director, assistant treasurer, meeting coordinator, session and workshop chair, and is presently its treasurer.

Related Sessions:

Genotoxic Impurities in
Pharmaceuticals Summit 2019

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities.
  • 11 Apr 2019
  • Berlin, DE
  • Pharma
Day 1: Thursday, 11 April 2019
CASE STUDY: Use of the Bacterial Reverse Mutation (Ames) Test to Evaluate Impurities.
  • Background and application
  • Case study
  • Use of miniaturized Ames assays to assess potential genotoxic impurities
  • Update on the OECD review of miniaturized bacterial mutagenicity assays
View Details

3rd Annual Genotoxic Impurities
in Pharmaceuticals Summit 2023

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 09 Mar 2023
  • Virtual,
  • Pharma
Day 2: Friday, 10 March 2023
CASE STUDY: Ongoing Efforts to Optimize the Ames Assay by the HESI-GTTC Mechanism-based Genotoxicity Risk Assessment (MGRA) Nitrosamine Subgroup
  • WG members and organization
  • Key protocol features and rationale
  • Proposed test articles and timing
  • Solicitation to join and/or help support the project
View Details